SCHEMBL612035

SCHEMBL612035

COC(=O)c1sc(Br)cc1NCc1ccncc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
MAPK10 P53779 3/20 0.45
MAPK8 P45983 2/20 0.45
ALDH1A1 P00352 5/20 0.43
EGFR P00533 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 1/20 0.42
KDR P35968 4/20 0.41
FLT1 P17948 3/20 0.41
GALR3 O60755 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23452086 0.87 CA1 (0.49) KMT2AL3MBTL1MAPK10MAPK8ALDH1A1
SCHEMBL1458749 0.86 RAF1 (0.46) POLBKMT2AL3MBTL1ALDH1A1MAPT
SCHEMBL614635 0.85 KDM4E (0.50) KMT2AALDH1A1KDM4EGAAMEN1
SCHEMBL611765 0.84 CDC7 (0.50) POLBKMT2AL3MBTL1ALDH1A1EGFR
SCHEMBL614632 0.79 MAPT (0.52) KMT2AALDH1A1EGFRKDM4EGAA
SCHEMBL612007 0.78 MAPT (0.56) POLBALDH1A1KDM4EMAPTLMNA
SCHEMBL613592 0.78 KDM4E (0.40) KMT2AL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL611970 0.76 MEN1 (0.55) POLBKMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL612156 0.74 MAPT (0.42) POLBKMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL5790723 0.73 ALDH1A1 (0.52) POLBKMT2AL3MBTL1MAPK10MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK POLB 1130/4885KMT2A 1565/4885L3MBTL1 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.